Exploring cellular senescence as a tumor suppressor mechanism

Clinical and Translational Oncology

Volumn 5, Issue 5, 2003, Pages 249-265

  Carnero, Amancio ^a   Blanco, Carmen ^a   Blanco, Fernando ^a   Castro, María E ^a   Guijarro, María V ^a   Fominaya, Jesús ^a   Link, Wolfgang ^a   Martínez, Juan F ^a   Moneo, Victoria ^a   Renner, Oliver ^a   Romero, Lourdes ^a   Rosado, Arantxa ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Cancer; Cell cycle; Cellular senescence; Chemotherapy; Immortalisation; Telomerase; Tumor supressors

Indexed keywords

EID: 33646253025     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (206)

1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-36.
2. Campisi J. The biology of replicative senescence. Eur J Cancer 1997;33:703-9.
3. Faragher R, Kipling D. How might replicative senescence contribute to human ageing? Bioessays 1998; 20(12):985-91.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Vojta PJ, Barrett JC. Genetic analysis of cellular senescence. BBA 1995;1242:29-41.
6. Rubin H. Cell aging in vivo and in vitro. Mech Ageing Dev 1997;98:1-35.
7. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in ageing skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
8. Martín GM. Cellular aging-clonal senescence. A review (Part I). Am J Pathol 1977;89:484-511.
9. Mendez MV, Stanley A, Park HY, et al. Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg 1998;28(5):876-83.
10. Norwood TH, Hoehn H, Salk D, et al. Cellular aging in Werner's syndrome: a unique phenotype? J Invest Dermatol 1979;73(1):92-6.
11. Fossel M. Telomerase and the aging cell: implications for human health. JAMA 1998; 279(21):1732-5.
12. Pawelec G, Remarque E, Barnett Y, et al. T cells and aging. Front Biosci 1998;3:d59-99.
13. Thomas E, Al-Baker E, Dropcova S, et al. Different kinetics of senescence in human fibroblasts and peritoneal mesothelial cells. Exp Cell Res 1997;236:355-8.
14. Rubin H. The disparity between human cell senescence in vitro and lifelong replication in vivo. Nat Biotech 2002;20:675-81.
15. Brooks RF, Richmond FN, Riddle PN, Richmond KM. Apparent heterogeneity in the response of quiescent Swiss 3T3 cells to serum growth factors: implications for the transition probability model and parallels with cellular senescence and competence. J Cell Physiol 1984; 121:341-50.
16. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973;41:181-90.
17. Kipling D. The Telomere. Oxford: Oxford University Press, 1995.
18. Morin GB. The implications of telomerase biochemistry for human disease. Eur J Cancer 1997;33:750-60.
19. de Lange T. Activation of telomerase in a human tumour. Proc Natl Acad Sci USA 1994;91:2882-5.
20. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 1995;5:249-55.
21. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-7.
22. Wynford-Thomas D, Bond JA, Wylie FS, Jones CJ. Does telomere shortening drive selection for p53 mutation in human cancer? Mol Carcinogen 1995;12:119-23.
23. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
24. Ramírez RD, Morales CP, Herbert BS, et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev 2001; 15(4):398-403.
25. Blackburn E. Telomere states and cell fates. Nature 2000;408:53-6.
26. Yang J, Chang E, Cherry AM, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem 1999;274:26141-8.
27. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997-3007.
28. Gallimore PH, Lecane PS, Roberts S, et al. Adenovirus type 12 early region 1B 54K protein significantly extends the life span of normal mammalian cells in culture. J Virol 1997;71(9):6629-40.
29. Kipling D, Cooke HJ. Hypervariable ultra-long telomeres in mice. Nature 1990;347:400-2.
30. Wynford-Thomas D. In vitro models of thyroid cancer. Cancer Surv 1993;16:115-33.
31. Kang MK, Guo W, Park NH. Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres. Cell Growth Diff 1998;9:85-95.
32. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997;94:13677-82.
33. Neumann AA, Reddel RR. Telomere maintenance and cancer -look, no telomerase. Nat Rev Cancer 2002;2: 879-84.
34. Mathon NF, Malcolm DS, Harrisingh MC, Cheng L, Lloyd AC. Lack of replicative senescence in normal rodent glia. Science 2001;291(5505):872-5.
35. Shay J, Wright WE. When do telomeres matter? Science 2001;291:839-40.
36. Sherr CJ, De Pinho RA. Cellular senescence: mitotic clock or culture shock. Cell 2000;102:407-10.
37. Tang DG, Tokumoto YM, Apperly JA, Lloyd AC, Raff MC. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 2001;291(5505): 868-71.
38. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999;402(6759):309-13.
39. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumours and tumour-derived cell lines. Nature Med 1997;3: 1271-4.
40. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14: 4240-8.
41. Yeager TR, Neumann AA, Englezou A, et al. Increased p16 levels correlate with pRB alterations in human urothelial cells. Cancer Res 1999;59(17):4175-9.
42. Wyndford-Thomas D, Kipling D. Telomeres, cancer and the knockout mouse. Nature 1997;389:551-2.
43. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
44. Foster SA, Galloway DA. Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene 1996;12: 1773-9.
45. Girardi AJ, Jensen FC, Koprowski H. SV40-induced transformation of human diploid cells: Crisis and recovery. J Cell Comp Physiol 1965;65:69-84.
46. Huschtscha LI, Holliday R. Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts. J Cell Sci 1983;63:77-99.
47. Shay JW, Wright WE. Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp Cell Res1989;184:109-18.
48. Bryan TM, Reddel RR. SV40-induced immortalization of human cells. Crit Rev Oncog 1994;5:331-57.
49. Hahn WC, Dessain SK, Brooks MW, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002; 22(7):2111-23.
50. Campisi J. Replicative senescence: an old lives' tale? Cell 1996;84(4):497-500.
51. Van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998;92:401-13.
52. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 2001:33A:787-91.
53. Counter CM, Hahn WC, Wei W, et al. Telomerase activity in normal leukocytes and in hematologic malignancies. Proc Natl Acad Sci U S A 1998;95(25):14723-8.
54. Krimpenfort P, Quon KC, Mooi WJ, et al. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001;413(6851):83-6.
55. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response and cancer in aging telomerase-deficient mice. Cell 1999;96:701-12.
56. Artandi SE, DePinho RA. Mice without telomerase: what can they teach us about human cancer? Nature Med 2000;6:852-5.
57. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-5.
58. Chin L, Artandi SG, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-38.
59. Vulliamy TJ, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413: 432-5.
60. Marciniak R, Guarente L. Testing telomerase. Nature 2001;413:370-2.
61. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998;8(6):351-4.
62. Bowles JT. The evolution of aging: a new approach to an old problem of biology. Med Hypotheses 1998;51(3): 179-221.
63. Howard BH. Replicative senescence: considerations relating to the stability of heterochromatin domains. Exp Gerontol 1996;31(1-2):281-93.
64. Wilson VL, Jones PA. DNA methylation decreases in aging but not in immortal cells. Science 1983; 220(4601):1055-7.
65. Sinclair DA, Guarente L. Extrachromosomal rDNA circles-a cause of aging in yeast. Cell 1997;91(7):1033-42.
66. Kunisada T, Yamagishi H, Ogita Z, et al. Appearance of extrachromosomal circular DNAs during in vivo and in vitro ageing of mammalian cells. Mech Ageing Dev 1985;29(1):89-99.
67. Troen BR. The biology of aging. Mt Sinai J Med 2003;70(1):3-22.
68. De Souza-Pinto NC, Bohr VA. The mitochondrial theory of aging: involvement of mitochondrial DNA damage and repair. Int Rev Neurobiol 2002;53:519-34.
69. Barja G. Rate of generation of oxidative stress-related damage and animal longevity. Free Radic Biol Med 2002;33(9):1167-72.
70. Hamilton ML, Van Remmen H, Drarse JA, et al. Does oxidative damage to DNA increase with age? Proc Natl Acad Sci USA 2001;98:10469-74.
71. Richter C. Oxidative Stress, Mitochondria, and Apoptosis. Restor Neurol Neurosci 1998;12(2,3):59-62.
72. Von Zglinicki T, Saretzki G, Docke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res 1995; 220: 186-93.
73. Reddel RR. A reassessment of the telomere hypothesis of senescence. Bioessays 1998;20:977-84.
74. Bohr V, Anson RM, Mazur S, Dianov G. Oxidative DNA damage processing and changes with aging. Toxicol Lett 1998;102-103:47-5275.
75. Harada YN, Shiomi N, Koike M, et al. Postnatal growth failure, short life span, and early onset of cellular senescence and subsequent immortalization in mice lacking the xeroderma pigmentosum group G gene. Mol Cell Biol 1999;19(3):2366-72.
76. Morimatsu M, Donoho G, Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gam-ma-radiation and premature senescence. Cancer Res 1998;58(15):3441-7.
77. Melov S, Ravenscroft J, Malik S, et al. Extension of lifespan with superoxide dismutase/catalase mimetics. Science 2000;289(5484):1567-9.
78. Melov S. Animal models of oxidative stress, aging, and therapeutic antioxidant interventions. Int J Biochem Cell Biol 2002;34(11):1395-400.
79. De Boer J, Andressoo JO, de Wit J, et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002;296(5571):1276-9.
80. Lehmann A. Ageing: repair and transcription keep us from premature ageing. Curr Biol 2002;12(16):R550-1.
81. Hart RW, Setlow RB. Correlation between deoxyribonucleic acid excision-repair and life-span in a number of mammalian species. Proc Natl Acad Sci USA 1974; 71:2169-73.
82. Treuting PM, Hopkins HC, Ware CA, et al. Generation of genetically altered mouse models for aging studies. Exp Mol Pathol 2002;72(1):49-55.
83. Vaziri H. Critical telomere shortening regulated by the ataxia-telangiectasia gene acts as a DNA damage signal leading to activation of p53 protein and limited lifespan of human diploid fibroblasts. A review. Biochemistry (Mosc) 1997;62(11):1306-10.
84. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Exp Gerontol 1996;31:295-301.
85. Hoopes LL, Budd M, Choe W, Weitao T, Campbell JL. Mutations in DNA replication genes reduce yeast life span. Mol Cell Biol 2002;22(12):4136-46.
86. Imamura O, Fujita K, Itoh C, et al. Werner and Bloom helicases are involved in DNA repair in a complementary fashion. Oncogene 2002;21(6):954-63.
87. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp Gerontol 1997;32(1-2):105-9.
88. Cuervo AM, Dice JF. How do intracellular proteolytic systems change with age? Front Biosci 1998;3:D25-43.
89. Dice JF. Cellular and molecular mechanisms of aging. Physiol Rev 1993;73(1):149-59.
90. Rattan SI. Synthesis, modifications, and turnover of proteins during aging. Exp Gerontol 1996;31(1-2):33-47.
91. Shikama N, Brack C. Changes in the expression of genes involved in protein synthesis during Drosophila aging. Gerontology 1996;42(3):123-36.
92. Merker K, Grune T. Proteolysis of oxidised proteins and cellular senescence. Exp Gerontol 2000;35(6-7):779-86.
93. Poot M. Oxidants and antioxidants in proliferative senescence. Mutat Res 1991;256(2-6):177-89.
94. Sohal RS, Brunk UT. Mitochondrial production of prooxidants and cellular senescence. Mutat Res 1992; 275(3-6):295-304.
95. Cuervo AM, Dice JF. When lysosomes get old. Exp Gerontol 2000;35(2):119-31.
96. Angello JC, Pendergrass WR, Norwood TH, Prothero J. Cell enlargement: one possible mechanism underlying cellular senescence. J Cell Physiol 1989;140(2):288-94.
97. Caldini R, Chevanne M, Mocali A, Tombaccini D, Paoletti F. Premature induction of aging in sublethally H2O2-treated young MRC5 fibroblasts correlates with increased glutathione peroxidase levels and resistance to DNA breakage. Mech Ageing Dev 1998;105(1-2):137-50.
98. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 1994;9:1885-9.
99. Carnero A, Hudson JD, Hannon GJ, Beach DH. Loss-offunction genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acid Research 2000;28: 2234-41.
100. Rogan EM, Bryan TM, Hukku B, et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995;15:4745-53.
101. Wynford-Thomas D. p53: Guardian of cellular senescence. J Pathol 1996;180:118-21.
102. Atadja P, Wong H, Garkavtsev I, Geillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci USA 1995;92:8348-52.
103. Bond J, Haughton M, Blaydes J, et al. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene 1996; 13:2097-104.
104. Ball KL, Lain S, Fahraeus R, Smythe C, Lane DP. Cellcycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 1997;7(1):71-80.
105. Garkavtsev I, Grigorian IA, Ossovskaya VS, et al. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 1998;391(6664): 295-8.
106. Garkavtsev I, Riabowol K. Extension of the replicative lifespan of human diploid fibroblasts by inhibition of the p33ING1 candidate tumour suppressor. Mol Cell Biol 1997;17:2014-9.
107. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27(9):462-7.
108. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242(1-2):15-29.
109. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999;18(53):7637-43.
110. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
111. Blaydes JP, Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 1998;16:3317-22.
112. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91: 649-59.
113. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 2000;21(5):865-9.
114. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12(15): 2424-33.
115. Alcorta DA, Xiong Y, Phelps D, et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996;93:13742-7.
116. Hall M, Peters G. Genetic alterations of cyclins, cyclindependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
117. Hara E, Smith R, Parry D, et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16:859-67.
118. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001;54(4):215-21.
119. Serrano M, Lee H, Chin L, Cordo C, Beach D, De Pinho Ra, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
120. Carnero A, Hudson JD, Price CM, Beach DB. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol 2000;2:148-55.
121. Carnero A. Cell cycle and Cancer. Rev Oncol 2000;2:28-40.
122. Stein GH, Drullinger LF, Soulard A, et al. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999;19(3): 2109-17.
123. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
124. Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999;18(35):4974-82.
125. Bond JA, Blaydes JP, Rowson J, et al. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res 1995;55:2404-9.
126. Tahara H, Sato E, Noda A, Ide T. Increase in expression level of p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 1995;10:835-40.
127. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998;227:43-55.
128. Wazer DE, Liu X-L, Chu Q, Gao Q, Band V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci USA 1995;92:3687-91.
129. Mulligan G, Jacks T. The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 1998;14(6):223-9.
130. Palmero I, McConnell B, Parry D, et al. Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene 1997;15:495-503.
131. Loughran O, Malliri A, Owens D, et al. Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene 1996;13:561-8.
132. Reznikoff CA, Yeager TR, Belair CD, et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 1996;56: 2886-90.
133. Erickson S, Sangfelt O, Heyman M, Castro J, Eintorn S, Grander D. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence. Oncogene 1998;17: 595-602.
134. Robles SJ, Adami GR. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 1998;16:1113-23.
135. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA. Evidence that exposure of the telomere 3' overhang sequence induces senescence. Proc Natl Acad Sci USA 2003; 100(2):527-31.
136. Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 1995;55:2892-5.
137. Foster SA, Wong DJ, Barrett MT, Galloway DA. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998;18: 1793-801.
138. Huschtscha LI, Noble JR, Neumann AA, et al. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 1998;58:3508-12.
139. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-9.
140. Robles SJ, Buehler PW, Negrusz A, Adami GR. Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochem Pharmacol 1999;58(4):675-85.
141. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001;413(6851):86-91.
142. Wolfel T, Hauer M, Schneider J, et al. A p16INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269(5228): 1281-4.
143. Sotillo R, Dubus P, Martin J, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 2001;20(23): 6637-47.
144. Sotillo R, Garcia JF, Ortega S, et al. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA 2001;98(23):13312-7.
145. Noble JR, Rogan EM, Neumann AA, Maclean K, Bryan TM, Reddel RR. Association of extended in vitro proliferative potential with loss of p16INK4 expression. Oncogene 1996;13:1259-68.
146. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378(2):F115-77.
147. Jiang XR, Jimenez G, Chang E, et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genet 1999;21:111-4.
148. Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genet 1999;21:115-8.
149. Vaziri H, Benchimol S. Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. Oncogene 1999;18(53): 7676-80.
150. Kiyono T, Foster SA, Koop JI, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396(6706):84-8.
151. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000;346 Pt 3:561-76.
152. Rodríguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370(6490):527-32.
153. Collado M, Medema RH, Garcia-Cao I, et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 2000;275(29):21960-8.
154. Tresini M, Mawal-Dewan M, Cristofalo VJ, Sell C. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts. Cancer Res 1998;58(1):1-4.
155. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci 1998;3:D250-68.
156. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998;12(12):1769-74.
157. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998;395(6698): 125-6.
158. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88(5):593-602.
159. Lee AC, Fenster BE, Ito H, et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999;274(12):7936-40.
160. Wei S, Wei S, Sedivy JM. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res 1999;59(7): 1539-43.
161. Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev 1998;12(19):3008-19.
162. Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 2000;20:273-85.
163. Brookes S, Rowe J, Ruas M, et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002;21(12):2936-45.
164. Chen KY. Transcription factors and the down-regulation of g1/s boundary genes in human diploid fibroblasts during senescence. Front Biosci 1997;2:d417-26.
165. Kowalik TF, DeGregori J, Leone G, et al. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998;9(2):113-8.
166. Pan H, Yin C, Dyson NJ, et al. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell 1998;2(3):283-92.
167. Nowell PC. Mechanisms of tumor progression. Cancer Res 1986;46(5):2203-7.
168. Munro J, Stott FJ, Vousden KH, Peters G, Parkinson EK. Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization et al. Cancer Res 1999;59(11):2516-21.
169. Paraskeva C, Finerty S, Powell S. Immortalization of a human colorectal adenoma cell line by continuous in vitro passage: possible involvement of chromosome 1 in tumour progression. Int J Cancer 1988;41:908-12.
170. Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Hormone Res 1997;47:145-7.
171. Hahn WC, Stewart SA, Brooks HW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-70.
172. Seger YR, Garcia-Cao M, Piccinin S, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002;2(5):401-13.
173. Loughran O, Clark LJ, Bond J, et al. Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes. Oncogene 1997;14:1955-64.
174. Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 1997;94(18):9648-53.
175. Oshimura M, Barrett JC. Multiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer 1997;33:710-5.
176. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
177. Holt SE, Wright WE, Shay JW. Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997;33,761-6.
178. Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 1999;59:4004-11.
179. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998;16:3323-30.
180. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999;13:2388-99.
181. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996;93:14025-9.
182. Harley CB, Kim NW, Prowse KR, et al. Telomerase, cell immortality, and cancer. Cold Spring Harbor Symp Quant Biol 1994;59:307-15.
183. De Lange T, Shine L, Myers RN, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-27.
184. Hastie ND, Dempster M, Dunlop MG, Thomson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346:866-8.
185. Vulliamy TJ, Knight S., Mason PJ, Dokal I. Very short telomeres in the peripheral blood of patients with Xlinked and autosomal dyskeratosis congenita. Blood Cells Mol Dis 2001; 27:353-7.
186. Hande MP, Samper E, Lansdorp P, Blasco MA. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol 1999;144:589-601.
187. Lee HW, Blasco NA, Gottlieb GJ, et al. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392: 569-74.
188. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci USA 1988; 85:6042-6.
189. Vogt M, Haggblom C, Yeargin J, et al. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Diff 1998;9:139-46.
190. Xu HJ, Zhou Y, Ji W, et al. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 1997;15(21):2589-96.
191. Hicks GG, Egan SE, Greenberg AH, Mowat M. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest Mol Cell Biol 1991;11:1344-52.
192. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989;49:3713-21.
193. Sager R. Senescence as a mode of tumor suppression. Environ. Health Pers 1991;93:59-62.
194. Fang L, Igarashi M, Leung J. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 1999;18(18):2789-97.
195. Carnero A. Targeting the cell cycle for cancer therapy. British J Cancer 2002;87(2):129-30.
196. Bonfanti M, Taverna S, Salmona M, et al. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997; 57(8):1442-6.
197. Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann N Y Acad Sci 2000;908:111-25.
198. Chang BD, Broude EV, Dokmanovic M, et al, A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999;59(15):3761-7.
199. Xiao H, Hasegawa T, Miyaishi O, Ohkusu K, Isobe K. Sodium butyrate induces NIH3T3 cells to senescencelike state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner. Biochem Biophys Res Commun 1997;237:457-60.
200. Wang X, Wong SC, Pan J, et al. Evidence of cisplatininduced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res 1998;58(22):5019-22.
201. Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999;18:4808-18.
202. Lodygin D, Menssen A, Hermeking HR. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest 2002;110(11):1717-27.
203. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109(3): 335-46.
204. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999;13(20): 2670-7.
205. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6(9):1029-35.
206. Schwartz AG, Moore CJ. Inverse correlation between species life span and capacity of cultured fibroblasts to bind 7,12-dimethylbenz(a)anthracene to DNA. Exp Cell Res. 1977;109(2):448-50.